Table 5.
Effect of treatment1 on biomarkers of systemic oxidative status and oxidative status of the gastrointestinal tract
| Diet2 | ||||||
|---|---|---|---|---|---|---|
| Item | LF | HF | HF + XY | HF + AX | Pooled SEM |
Treatment P-value |
| Serum | ||||||
| TAC3, mM | 4.26a | 4.35a | 6.89b | 4.73a | 1.15 | 0.047 |
| MDA,μmol/μL | 15.12 | 16.38 | 13.26 | 16.79 | 1.94 | 0.098 |
| Ileal tissue | ||||||
| TAC, mM | 2.31a | 2.52a | 3.35b | 2.51a | 0.15 | 0.037 |
| MDA, μmol/mg | 3.55 | 2.38 | 2.64 | 1.89 | 0.32 | 0.108 |
| Colonic tissue | ||||||
| TAC, mM | 5.34 | 5.81 | 5.87 | 5.79 | 0.27 | 0.432 |
| MDA, μmol/mg | 4.27a | 2.86b | 3.18b | 2.40b | 0.80 | 0.041 |
1 n = 15 pigs per treatment fed experimental diets for a 36-d adaptation period followed by a 10-d metabolism crate study.
2LF, low-fiber control; HF, high-fiber control; HF+XY, high-fiber control containing 100 mg xylanase/kg; HF+AX, high-fiber control containing 50 mg arabinoxylanoligosaccharide/kg.
3TAC was measured as a sample’s ability to inhibit the oxidation of 2,2′-Azino-di-3-ethylbenzothiazoline sulfonate and quantified as millimolar Trolox equivalents.
a, bWithin a row, means without a common superscript differ (P ≤ 0.05).